Home Magazines Editors-in-Chief FAQs Contact Us

Effectiveness and baseline predictive factors for Tofacitinib response in rheumatoid arthritis in a real-world setting: A national multicenter study

MOJ Orthopedics & Rheumatology
Vinicki JP,1  Gomez R,2 Maliandi MR,3 Velasco Zamora JL,4 Malvano YS,5 Cusa MA,6 Gamba MJ,2 Got J,7 Gut O,8 Paris V,9 Spinetto MA,8 Mariasch NC,8 Abalo AI,10 Estevez AJ10

PDF Full Text


  1. Background:Evidence of effectiveness and safety of tofacitinib (TOF) in the real-world setting in Latin America is currently limited and crucial to complement long-term extension data from randomized controlled trials.
  2. Methods:Patients initiated on TOF between 2014 and 2020 with RA (ACR/EULAR, 2010 criteria)were analyzed. The primary end point at month 3 was remission measured by DAS28-ESR. Secondary end points includedprognostic factors for remission at 3 months and of monotherapy at month 12.
  3. Results:Overall, 134 RA patients were analyzed. Remission was achieved in 38.06% at month 3. In univariate analysis, persistent disease activity at 3 months was observed in those patients with longer duration of disease, structural radiological damage, higher baseline DAS28-ESR and greater frequency in previous use of bDMARD. In multivariate analysis, previous use of bDMARD was significantly associated with a decrease in the probability of remission at 3 months. At 12 months, TOF monotherapy group was elderly (p = 0.009) and had a trend for lower frequency of anti-CCP. Treatment persistence was 94.78% at 3 months, 82.84% at 6 months and 66.42% at 12 months.
  4. Conclusions:Clinical remission at 3 months was negatively associated with prior bDMARD and poor prognostic factors. TOF monotherapy at 12 months was more common in elderly patients.


: tofacitinib, Janus kinase inhibitor, rheumatoid arthritis, real-world settings, daily clinical practice